Suppr超能文献

异基因造血干细胞移植后慢性淋巴细胞白血病患者使用依鲁替尼成功治疗Richter转化

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant.

作者信息

Master Samip, Leary Cheri, Takalkar Amol, Coltelingam James, Mansour Richard, Mills Glenn M, Koshy Nebu

机构信息

Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.

出版信息

Case Rep Oncol. 2017 Jun 19;10(2):534-541. doi: 10.1159/000477338. eCollection 2017 May-Aug.

Abstract

Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to multi-agent chemotherapy and was started on ibrutinib. She had a complete response for 16 months on single-agent ibrutinib with minimal toxicity.

摘要

进展为Richter转化(RT)的慢性淋巴细胞白血病(CLL)患者预后较差。多药化疗方案的缓解率不佳。关于伊布替尼在RT中的应用仅有少数病例报告。在此,我们报告一名曾接受包括异基因干细胞移植在内的多种CLL预处理方案且进展为RT的患者。她对多药化疗反应不一,随后开始使用伊布替尼。她单药使用伊布替尼16个月,达到完全缓解,且毒性极小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ba1/5498945/151896522453/cro-0010-0534-g01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验